MRNA Moderna, Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
At the channel ceiling · 18-month channel rising
Price is at the upper line, where it has stalled before.
- 18-month channel read from
- US$68.81 – US$240.21 · rising, more than +100% a year
- 12-month channel
- US$225.85 – US$282.08 · rising, more than +100% a year
- Price in channel
- 89% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$240.21
- Turns bearish below
- US$68.81
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 7:25 AM ET (76 h ago)
- Daily close
- Upper trend line (18 months)
- Lower trend line (18 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$159.15
level as at 4 Dec 2026
Our target
US$286.51
by 28 Jan 2027
Projected move
80.0%
gross, before costs
Price is between our buy and target.
Target: the projected upper line.
This move size: reached in 10% of 21 past stretches, typically in 90 days. (0.89% per day)
- Upper line touches
- 3
- Lower line touches
- 2
- Fit confidence
- 27%
- Fitted
- 1 Nov 2026
Company information
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel
- Employees
- 4,700
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- 67/100
- Profitability
- 0/100
- Financial health
- 54/100
- Cash generation
- 0/100
Key statistics
- Market cap
- US$85.50B
- Enterprise value
- US$85.07B
- Beta
- 0.90
- Avg volume
- 17.18M
- Revenue per share
- 5.63
- Dividend yield
- 0.00%
- 52-week range
- 22.28-254.48
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- -26.84
- PEG
- 3.18
- Price / sales
- 38.38
- Price / book
- 12.54
- EV / EBITDA
- -30.07
- Gross margin
- -12.57%
- Operating margin
- -149.01%
- Net margin
- -141.43%
- Current ratio
- 2.29
- Quick ratio
- 2.18
- Debt / equity
- 0.19
- Interest cover
- -132.80
Income statement
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | US$1.94B | US$1.08B | -US$3.07B | -US$2.82B | -US$7.26 |
| 2024 | US$3.20B | US$1.74B | -US$3.94B | -US$3.56B | -US$9.27 |
| 2023 | US$6.85B | US$2.15B | -US$4.24B | -US$4.71B | -US$12.34 |
| 2022 | US$18.88B | US$13.46B | US$9.42B | US$8.36B | US$20.10 |
| 2021 | US$17.74B | US$15.12B | US$13.30B | US$12.20B | US$28.29 |
Balance sheet
| Year | Total assets | Total liabilities | Total equity |
|---|---|---|---|
| 2025 | US$12.34B | US$3.69B | US$8.65B |
| 2024 | US$14.14B | US$3.24B | US$10.90B |
| 2023 | US$18.43B | US$4.57B | US$13.85B |
| 2022 | US$25.86B | US$6.74B | US$19.12B |
| 2021 | US$24.67B | US$10.52B | US$14.14B |
Cash flow
| Year | Operating cash flow | Free cash flow | Net income |
|---|---|---|---|
| 2025 | -US$1.87B | -US$2.06B | -US$2.82B |
| 2024 | -US$3.00B | -US$4.05B | -US$3.56B |
| 2023 | -US$3.12B | -US$3.83B | -US$4.71B |
| 2022 | US$4.98B | US$4.58B | US$8.36B |
| 2021 | US$13.62B | US$13.34B | US$12.20B |
EPS forecasts
| Period | Est. EPS | Est. revenue | Analysts |
|---|---|---|---|
| 2025 | -US$7.84 | US$1.91B | 15 |
| 2026 | -US$8.42 | US$2.10B | 17 |
| 2027 | -US$4.76 | US$2.43B | 16 |
| 2028 | -US$2.85 | US$3.38B | 15 |
| 2029 | US$0.3558 | US$5.56B | 9 |
| 2030 | US$3.52 | US$7.58B | 6 |
Analyst view
- Target (mean)
- US$132.70
- Target (high)
- US$245.00
- Target (low)
- US$25.00
- Strong buy
- 0
- Buy
- 7
- Hold
- 16
- Sell
- 6
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.